Imunon, Inc. is a biotechnology enterprise operating at the clinical development stage, dedicated to the advancement and commercialization of innovative DNA-centric immunotherapeutic agents, vaccines, and targeted chemotherapy treatments. Its product pipeline prominently features GEN-1, a DNA-based immunotherapy specifically designed for the localized management of ovarian cancer. Alongside this, the company is developing ThermoDox, a proprietary liposomal formulation of doxorubicin that is activated by heat, currently being explored for various oncological indications.